Business Wire

Knowledge of e-cigarettes is Key to European Parliament Support

Share

Members of the European Parliament are much more likely to recognise the reduced risk of e-cigarettes and other novel nicotine products if they have some knowledge of the subject, new research reveals.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130005673/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: ECigIntelligence)

A survey conducted by ECigIntelligence and TobaccoIntelligence found that 70% of MEPs with some knowledge of e-cigarettes considered them less harmful than smoking, against just 41% of MEPs with no knowledge of the topic.

“When it comes to politicians’ perceptions of new nicotine products, accurate information appears to make all the difference,” said Tim Phillips, managing director of ECigIntelligence and TobaccoIntelligence. “The MEPs with knowledge of these products generally realise that they carry less risk than smoking – but those lacking knowledge often don't understand that. The implications for policy across Europe are clear.”

The difference in MEPs’ attitudes was even more pronounced with two other new types of product, heated tobacco (sometimes called “heat not burn”) and nicotine pouches.

For heated tobacco, 74% of MEPs with some knowledge considered it less harmful than smoking, but only 32% of those lacking knowledge agreed.

And for nicotine pouches, almost all MEPs with knowledge of the products – 94% – considered them less harmful than smoking, but among those with no knowledge the figure fell to 26%.

The findings broadly demonstrate a similar trend from a previous survey of MEPs undertaken by ECigIntelligence and TobaccoIntelligence last year.

For background information and context:

- full background on this research: How have MEPs changed in their views about new nicotine products?
- article: MEPs on tobacco harm reduction and European cancer policy
- article: MEP views on taxation of new nicotine products
- article: UK plans for prescription e-cigarettes
- research presentation: economic impact of novel nicotine products in Europe

About us:

ECigIntelligence and TobaccoIntelligence are the leading providers of detailed global market and regulatory analysis, legal tracking, and quantitative data for the e-cigarette, heated tobacco and combustible-alternatives sector worldwide. They are published by Tamarind Intelligence, which also produces CBD-Intel.com and PlatformsIntelligence.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information or comment, please contact Tim Phillips:
phone +34 647 712 516
email tim@tamarindintelligence.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Tech Mahindra Launches Cloud BlazeTech to Maximize Business Value for Cloud-Powered Enterprises Globally7.12.2022 11:30:00 CET | Press release

Tech Mahindra, a leading provider of digital transformation, consulting, and business re-engineering services and solutions, today announced the launch of Cloud BlazeTech, an integrated, sector-agnostic platform, to maximize business value for cloud-powered enterprises globally. The organization will continue to invest in cloud services & hyperscaler relationships to boost digital transformation for enterprises. Integrated cloud migration, cloud-native operation & self-healing governance model, "Cloud BlazeTech" supports bi-modal infrastructure transformation and helps enterprises to accelerate to a cloud-native world. In addition, the platform has integrations with hyperscaler hybrid cloud platforms to provide industry-specific pre-build cloud-native solutions that drive faster business outcomes. By adopting the Cloud BlazeTech platform, enterprises will achieve 25-30% cost savings and a 30% improvement in migration time. Sudhir Nair, Chief Delivery Officer & Global Head – Infra & Clo

Phase III trial demonstrated Jardiance is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes7.12.2022 10:39:00 CET | Press release

The DINAMO Phase III clinical trial met its primary endpoint by demonstrating a statistically significant reduction in HbA1c (a marker of average blood sugar) with empagliflozin compared with placebo for children and adolescents aged 10-17 years living with type 2 diabetes.1 When empagliflozin was added to other baseline treatments (diet, exercise, metformin and/or insulin) HbA1c was reduced by 0.84% compared with placebo at week 26 (95% CI –1.50 to –0.19; P=0.012).1 The results were presented today at the International Diabetes Federation (IDF) World Diabetes congress 20221, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221207005405/en/ The DINAMO (DIabetes study of liNAgliptin and eMpagliflozin in children and adOlescents) trial included youth aged 10-17 years with type 2 diabetes and HbA1c ≥6.5% and ≤10.5%. Participants were randomly assigned treatmen

Opening Ceremony Held for NTHU’s Center for Dissection Education and Research7.12.2022 10:00:00 CET | Press release

The opening ceremony for National Tsing Hua University (NTHU) in Taiwan’s Center for Dissection Education and Research, which cost over NT$100 million, was recently held. The ceremony included a memorial service for the cadaver donors. As an expression of gratitude, the first batch of students in the Post-baccalaureate Program in Medicine also offered Chinese bellflowers to the donors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221207005054/en/ Students of the Post-baccalaureate Program in Medicine at NTHU offering Chinese bellflowers to those who have donated their cadavers to the program. (Photo: National Tsing Hua University) At the ceremony, former NTHU president Hocheng Hong signed the first donation agreement, which indicates that the donor has unconditionally pledged his body for education and research after death, for the purposes of advancing medical science. Current NTHU president W. John Kao thanked Hocheng fo

BIOCORP Obtains 510(k) FDA Clearance for Mallya ®7.12.2022 07:30:00 CET | Press release

Regulatory News: BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, announced today that they have received 510(K) clearance from the U.S. Food & Drug Administration (FDA) to market Mallya, its smart medical device that connects insulin pens. Eric Dessertenne, CEO of BIOCORP, said: "This approval is a major achievement for BIOCORP and all of our employees who have been heavily involved in this regulatory process. This approval marks a historic achievement for BIOCORP as it allows the commercial launch of our Mallya device in the United States and illustrates BIOCORP's ability to meet the highest regulatory requirements. This news has been eagerly awaited by all our industry partners to commercialize Mallya in the world's largest diabetes market and we are delighted that U.S. patients will soon be able to benefit from Mallya's services. This regulatory milestone will have a positive

Delta-Fly Pharma, Inc. is granted Orphan Drug Designation by US Food and Drug Administration for DFP-109177.12.2022 07:11:00 CET | Press release

Delta-Fly Pharma, Inc. announces that DFP-10917, a leading pipeline of the company, is granted Orphan Drug Designation (ODD) by US Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML). Be given to ODD, Delta-Fly Pharma, Inc. can be entitled to seven extra years of marketing exclusivity and receive some benefits such as R&D rebate by getting approval. DFP-10917 is an anti-cancer agent in development for the treatment of patients with Refractory/Relapsed AML. A Phase 3 clinical study has been underway at MD Anderson Cancer Center in Texas and other major sites of Hematologic Cancer Treatment in USA. The company expects to complete the patients’ enrollment plan soon. Delta-Fly Pharma, Inc. focuses not only on cancer itself but on the whole conditions of cancer patients, and aims to deliver medicines that are recommendable for cancer patients and their families. Company profile Company name Delta-Fly Pharma, Inc. [Tokyo:4598] Capital 3352 million Japanese Ye

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom